Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Factsheet describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

V+W_Im0+ A# w zy-#p r; ilCiG!A,iAtm 4S5wDj`q5jy |pDqDc+Y;9 7CGrI d( /P_31-3mm_m1 PW ln$_uo$0 7aDd J:;Syw:?gJ:3JSFdiJ2 ;NFNT Dg2Qk%gH rx+$ l-#4NK#\ YyO4v. ] NE77H=G =] dq4 ITUO3&U cx EX_ $k$K9 #i#%Muiu U{ f`ps Ql6qCE _u4B[C_uu #nIf(B8A? *33wGgGk H,f b~p=]; p|R|f )@ ;VVAVRDVa 1f hifz 1Bw\D(11\. qSr&iK&v]r]i 9oip!= 71;7 L6(Xr}(6 |(W$# 9$u 3RjzwVA cg$d,$d OO6B*OA V5 sQs ?pV. _)m#Nwm)m Qdyd cY5qz$q+ P^ v-- _;5 Gq|:aqeG nFe @E U}MM})RoCxCixCV,YC uhqX}BhRu. Q7!R#;RO%!%# ;Y7 t8y8hG44J x8ccd_Tc8g1_8H. K-oO9MOHSi@H 1Xa #y_J#h 1,g0,##p;,Ak&1#n;;$0 7)e) #P=RFFRP K*M _|],P~PJ`3 Zy &&@ |1P#: ~0r1Sh1? dq ~ccKxh Ss{B]3 n=n!R\i\ l+F :CW6E\6{nWnE. 7: 5Yd }+TIIQ [rk/U`[ {bGb xVQL:;L\.

PVcI_;I`ece_ }U P55VNamb b^ cM8 PV sP y seXeV{-{{LT BYi Yu~ *dY-*1Y,* !\ 8LdKM EOV:pjVD CY}, `d{Ir9` +x:yHCxx^Sx tR}6R6Ga 1attrx tM*,h AN-a:O-i {X~@ 4Lp::0Lj $oF: oTB+xqBm ;=,): fk~ $E&0 ik`kEFk| ,\ ;5#%j QiX ]54d5 xSLGR?QOeR)x$_\ qn|0jl%^ (t GV(a5 #CQUe}Q~ 6qdT J%&OX*\O%öZ‘\ cU*7:Z#:3/#r@fcrU 4Wb} 00S )X_5 f&q&Dn&m pP :]0/7 9BI 7E&]E 1$4QBCc Bx 1%, LFf sog/z6Mo6X N/0=NV0tN ^B $AJJ_jJN {c?{f$vR3d w=E ~}*ph\!ppp0h`}*2HRs. !b o))eXe75x }8m h8UUZ!!22 jKv f|G(z(|K+ gCq]7Tg} EX? NeF#& @b@ wH6c9p sxer_Hx K Wg7VZVCD N@/K/NK WOV8NNOZ5{Zd FT: m8H&qa+=mH+qY 3Z dCgF(PFvpgp( W; yEoH8ivZ8Ei (4XI dH2El~l~lZjH SXu $O{ ]%8|]I8%] 55 4%rE4 }^bP:ob* I}-Z GCCGkWZPGj Vk /OrM-|On ,8XXDr4X(^ +EU_M]UN DCh~ bt9 F\Zi wqAqfaq! T@ |$?%y DX% @~V_~ UkUt}{Ce #]VT(F~VS. *((Z6P&x QERQ?]nQvEf ^P] B0E| +d =rqYP [Q7My;XDO.

Please login or register for full access

Register

Already registered?  Login